PARATEK PHARMACEUTICALS INC's ticker is PRTK and the CUSIP is 699374302. A total of 113 filers reported holding PARATEK PHARMACEUTICALS INC in Q2 2018. The put-call ratio across all filers is 1.93 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2018 | $6,209,000 | -14.6% | 477,607 | +17.6% | 0.97% | -18.6% |
| Q4 2017 | $7,271,000 | -28.7% | 406,207 | 0.0% | 1.19% | -21.2% |
| Q3 2017 | $10,196,000 | +52.7% | 406,207 | +46.6% | 1.51% | +85.9% |
| Q2 2017 | $6,676,000 | +54.9% | 277,020 | +23.7% | 0.81% | +55.4% |
| Q1 2017 | $4,309,000 | -64.4% | 223,862 | -71.5% | 0.52% | -61.2% |
| Q4 2016 | $12,106,000 | +18.4% | 786,134 | 0.0% | 1.34% | +46.6% |
| Q3 2016 | $10,228,000 | -8.5% | 786,134 | -2.1% | 0.92% | -15.6% |
| Q2 2016 | $11,174,000 | +38.9% | 803,332 | +51.5% | 1.09% | +39.8% |
| Q1 2016 | $8,044,000 | -20.0% | 530,282 | -0.0% | 0.78% | +25.5% |
| Q4 2015 | $10,059,000 | -0.2% | 530,283 | 0.0% | 0.62% | +10.3% |
| Q3 2015 | $10,075,000 | -26.3% | 530,283 | 0.0% | 0.56% | -23.6% |
| Q2 2015 | $13,665,000 | +68.0% | 530,283 | +103.7% | 0.73% | +15.8% |
| Q1 2015 | $8,136,000 | -49.3% | 260,283 | -50.0% | 0.63% | -9.2% |
| Q4 2014 | $16,054,000 | – | 520,566 | – | 0.70% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Omega Fund Management, LLC | 2,600,410 | $36,172,000 | 26.83% |
| Abingworth LLP | 1,301,413 | $18,103,000 | 18.96% |
| Roumell Asset Management, LLC | 290,136 | $4,036,000 | 9.16% |
| Monashee Investment Management LLC | 100,000 | $1,391,000 | 2.19% |
| BVF INC/IL | 575,000 | $7,998,000 | 1.70% |
| Aisling Capital LLC | 482,680 | $6,714,000 | 1.59% |
| Opaleye Management Inc. | 146,700 | $2,041,000 | 1.36% |
| Broadfin Capital, LLC | 803,332 | $11,174,000 | 1.09% |
| GENERAL AMERICAN INVESTORS CO INC | 477,076 | $6,636,000 | 0.69% |
| Opus Point Partners Management, LLC | 37,665 | $524,000 | 0.51% |